Neurogene Inc. (NASDAQ: NGNE) had its price target lowered by analysts at BMO Capital Markets from $45.00 to $16.00. They now have an "outperform" rating on the stock.
Neurogene Inc. (NASDAQ: NGNE) was given a new $38.00 price target on by analysts at Robert W. Baird.
Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome [Yahoo! Finance]
Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome
Neurogene Inc. (NASDAQ: NGNE) had its "outperform" rating re-affirmed by analysts at William Blair.